about
Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to dateExtensive surface protein profiles of extracellular vesicles from cancer cells may provide diagnostic signatures from blood samples.ZAP-70 in B cell malignanciesA novel physical and functional association between nucleoside diphosphate kinase A and AMP-activated protein kinase alpha1 in liver and lungNDPK-A (but not NDPK-B) and AMPK alpha1 (but not AMPK alpha2) bind the cystic fibrosis transmembrane conductance regulator in epithelial cell membranes.The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemiaSurface profiles for subclassification of chronic lymphocytic leukemia.Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemia.Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia.Chronic lymphocytic leukaemia, monoclonal B-lymphocytosis and pregnancy: five cases, a literature review and discussion of management.The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine.Mechanisms of action of fludarabine nucleoside against human Raji lymphoma cells.DNA methylation of membrane-bound tyrosine phosphatase genes in acute lymphoblastic leukaemia.Hsp90 Inhibitor SNX-7081 dysregulates proteins involved with DNA repair and replication and the cell cycle in human chronic lymphocytic leukemia (CLL) cells.Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with fludarabine against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotype.Protein kinase CK2, cystic fibrosis transmembrane conductance regulator, and the deltaF508 mutation: F508 deletion disrupts a kinase-binding site.The phosphorylation status of membrane-bound nucleoside diphosphate kinase in epithelia and the role of AMP.The novel Hsp-90 inhibitor SNX7081 is significantly more potent than 17-AAG against primary CLL cells and a range of haematological cell lines, irrespective of lesions in the TP53 pathway.Type C TP53-CDKN1A pathway dysfunction occurs independently of CDKN1A gene polymorphisms in chronic lymphocytic leukaemia and is associated with TP53 abnormalities.Serum from a subset of patients with chronic lymphocytic leukemia and large local reactions to mosquito bites induces upregulation of CD63 surface expression on basophils in atopic donors.Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia.A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL.Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment.Surface Profiling of Extracellular Vesicles from Plasma or Ascites Fluid Using DotScan Antibody Microarrays.Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in Chronic Lymphocytic Leukaemia.Lymphoma cell-of-origin assignment by gene expression profiling is clinically meaningful across broad laboratory contexts.Monoclonal B-lymphocytosis in patients aged over 90 years is common but not inevitable, and has a prevalence comparable to that in individuals aged 65-90 years.The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironmentZAP-70 by flow cytometry: a comparison of different antibodies, anticoagulants, and methods of analysisA subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable diseaseProtein kinase C isoform expression in chronic lymphocytic leukemia: a potential target for therapy?Assessing pilot vial material as a surrogate for functional and phenotypic stem cell markers in cryopreserved haematopoietic stem cell productMEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironmentExpression of Intracellular Reactive Oxygen Species in Hematopoietic Stem Cells Correlates with Time to Neutrophil and Platelet Engraftment in Patients Undergoing Autologous Bone Marrow TransplantationImmune failure, infection and survival in chronic lymphocytic leukemiaMolecular pathogenesis of chronic lymphocytic leukaemia
P50
Q26798062-45384F55-FCA2-4444-8C98-63BC7570A219Q27303212-49CAA1D8-2084-4C4D-960F-DEEDE390E488Q28279902-2E7E3C28-ED2D-4B01-A1BF-D2240227C8C5Q28568418-229A2982-7C9A-4F66-B112-41D22A3FDD9EQ33233443-334554C3-4961-4326-92FB-6E0E27B6E55FQ36562242-B1BDCA69-0CB5-452C-B782-BF31BFCE66C1Q37948956-976042B7-C9CF-4325-8626-5E84FA06A85BQ38008448-AE51B61C-F507-45E8-8F75-8A18E950889CQ38167332-77475C5E-A987-44C1-AFFD-6679F25FD024Q38254406-94B24F81-070D-45D4-972E-71E5212EAACDQ38895643-1CF65F1D-E6D1-4662-B1B3-76675FA8C727Q38983480-70BE5A50-1662-47E5-A7E6-CD6D1F756673Q39094566-AC4A9B1D-B696-4BF4-8CE7-239DCF435883Q39185677-17B9F578-D9D0-4972-8AF6-F356BB616CB4Q39339803-B6CA4670-2F87-4839-A977-95A0A74ECE55Q40173032-AE8C5B48-E724-404A-89FD-80156AE3F0C9Q42722819-3EDBA7A7-46C9-452E-9EB0-06593F8D556BQ42926169-63C73899-D6C8-4655-B713-88486484D31FQ43627273-3FDFCEC7-EF82-4352-91A8-E1E87134B5B7Q44156932-A169A52F-5937-4028-B5CA-99C2F30F730FQ44893943-FCC45A9F-05A7-4C3B-87DF-1C2B937CB215Q46804701-9200709D-3E83-45A6-B9DA-BA96E0AF61BBQ49818504-44C1EFDB-2531-49DC-8055-0E50C7DD498AQ50908901-0B85F309-05CE-4033-BCE5-E32B737A6284Q53082166-B9BD20A9-80B9-4E06-BB84-F160CE16CE8BQ53505510-D97F2D91-BEAD-476F-B574-A63C385F4D44Q53667763-3D41A267-B0B5-4AB0-82D3-3F38120F772DQ59357535-DBF4BF25-80B1-4083-AF8C-698CD31C8DCDQ80103617-D9717D78-1264-4D42-ACB0-4B2CC328D3A7Q82081716-88B4366B-1144-47D3-8EF7-6695F86FCAADQ86306147-0AD3AEF0-D613-4C15-8F80-5C43948A0996Q88414976-994B5B4F-836E-4048-83F7-F3F40024B82CQ88690979-3EC05FBC-4453-408D-9C19-A0EF6AC30B28Q89187638-52409486-4247-40A0-B12A-37F1CF2B3FC3Q89410010-8F5705F5-5670-4135-B9AF-A5137FA710CAQ92303337-2EA79973-4A88-45BC-BE34-5C70D470507A
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
O Giles Best
@en
O Giles Best
@nl
type
label
O Giles Best
@en
O Giles Best
@nl
prefLabel
O Giles Best
@en
O Giles Best
@nl
P31
P496
0000-0003-2685-3880